MEDICAL RISK CLASSIFICATION FOR SEVERE COVID-19 BASED ON

CHRONIC MEDICAL CONDITIONS: A COMPARATIVE ANALYSIS

4452 words

Ilse Westerhof[1*], Annemarijn de Boer[1], Angela Lupattelli[2], Isabel Slurink[1], Otilia Boldea[3], Hedvig Marie Egeland Nordeng[2,4], Jizzo R. Bosdriesz[5,6,7,8], Frank Pijpers[9,10], Maarten Schim van der Loeff[6,7,8], Mirjam Knol[5], Janneke van de Wijgert[1,5], Patricia Bruijning[1], and Ganna Rozhnova[1,11,12,13]

[1]Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
[2] Pharmacoepidemiology and Drug Safety Research group, Department of Pharmacy, University of Oslo, Oslo, Norway
[3]Department of Econometrics and OR, Tilburg School of Economics and Management, Tilburg University, Tilburg, The Netherlands
[4] Department of Child Health and Development, National Institute of Public Health, Oslo, Norway
[5]Department of Infectious Disease Control, National Institute for Diseases, Public Health and the Environment, Bilthoven
[6]Amsterdam UMC location University of Amsterdam, Infectious Diseases, Meibergdreef 9, Amsterdam, the Netherlands
[7]Amsterdam Institute for Immunology & Infectious Diseases, Amsterdam, the Netherlands
[8]Department of Infectious Diseases, Public Health Service (GGD) of Amsterdam, Amsterdam, Netherlands.
[9]Statistics Netherlands, The Hague, Netherlands
[10]Korteweg-de Vries Institute for Mathematics, University of Amsterdam, Amsterdam, The Netherlands
[11]Center for Complex Systems Studies (CCSS), Utrecht University, Utrecht, The Netherlands
[12]BioISI—Biosystems & Integrative Sciences Institute, Faculdade de Ciências, University of Lisbon, Lisbon, Portugal
[13]Faculdade de Ciências, University of Lisbon, Lisbon, Portugal
[*] Corresponding author: Ilse Westerhof; i.westerhof-4@umcutrecht.nl

Abstract (299 words)

Background: The European Centre for Disease Prevention and Control provides listings of medical conditions conferring high- or moderate-risk for severe COVID-19. Additionally, individual European countries developed national risk classifications to guide COVID-19 vaccination recommendations.

Methods: This multi-country healthcare data-linkage study included 17.4 million inhabitants in the Netherlands and 5.6 million inhabitants in Norway in 2020. Medical conditions were defined using ICD-10 codes in the European and Dutch classifications, and ICD-10 and ICPC-2 codes in the Norwegian classification. Subjects were classified as high-, moderate-, or low-risk.

Findings: Discordance between European and national classification was 12.0% and 13.8% in the general population, 36.5% and 38.2% among hospitalized individuals, and 46.6% and 45.1% deceased individuals, in the Netherlands and Norway, respectively. The European classification assigned more individuals to high-risk, while national classifications assigned more individuals to moderate-risk. Classification discordances most frequently involved subjects with cardiovascular disease, lung disease, and diabetes mellitus.

Interpretation: The European classification defines a substantially larger proportion of the population as high-risk for severe COVID-19 compared to national classifications. This may have implications for post-pandemic vaccination programs. Further research should assess to what extent the discordant medical conditions determine the risk of developing severe COVID-19.

Funding: ZonMw, EU, FCT, Norwegian Research Council's COVID-19 Emergency Call, iAPOGEE.

Key words: Severe COVID-19 | Chronic medical conditions | Medical risk classification

Introduction

The impact of public health measures, including COVID-19 vaccination, depends on the accurate identification of populations at elevated risk for severe outcomes, including hospitalization and death [1]. The World Health Organization recommends targeting vaccination programs to population groups at the highest risk of severe COVID-19 [1], but disparities exist in the risk classifications developed by different health authorities. While COVID-19 currently presents as common cold- or flu-like illness, older individuals and those with certain chronic medical conditions still face higher hospitalization and death rates compared to the general population [2,3]. Most risk classifications group individuals into high-, moderate-, and low-risk for severe COVID-19, based on factors like medical conditions and age. High-risk individuals have chronic conditions that lead to a much higher likelihood of severe outcomes, while those in the moderate-risk group face an elevated but lower risk.

Informed by influenza risk classifications and studies on risk factors for severe COVID-19, national (e.g., the Health Council of the Netherlands[4] and the Public Health Institute in Norway [5]) and international (e.g., the European Centre for Disease Prevention and Control [6]) public health authorities assigned high- or moderate-risk of developing severe COVID-19 to specific pre-existing medical conditions. These medical risk classifications have remained unchanged [6,7] or undergone minor alterations [4,5,8,9] since their development at the beginning of the pandemic. They have continued to guide epidemiological research and policy decisions on eligibility criteria and prioritization for vaccination programs aimed at reducing the incidence of severe COVID-19. While these European and national

classifications can be applied within the same country, it is unclear to what extent they differ

in assigning medical risk status to individuals.

To inform evidence-based decision-making for severe COVID-19, we conducted a

comparative analysis of risk status in the respective national versus the European

classification. This observational national registry-based cohort study used Dutch and

Norwegian health and administrative data from 1 January 2020, linked at the individual level,

including 17.4 million inhabitants of the Netherlands and 5.6 million inhabitants of Norway.

We aimed to examine discordance between the respective national and European medical risk

classifications for severe COVID-19 for the Netherlands and Norway across general,

hospitalized, and deceased populations, and investigate related factors.

Methods

Data Collection

Data collection – The Netherlands

The Dutch dataset included hospital discharge registry (DHD) data for all inhabitants of the Netherlands as per the Dutch Population Registry on 1 January 2020, as well as individuals hospitalized and deceased due to COVID-19 in 2020. The two registries were linked using unique personal identification numbers. The Population Registry was used to extract age, immigration, and emigration dates. The DHD provided information on chronic medical conditions diagnosed in hospitals since 1 January 1995, including the date of diagnosis. All diagnoses were registered according to the International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10) [10].

Data collection – Norway

The Norwegian dataset included data from multiple Norwegian registries for all inhabitants of Norway as per the National Population Registry on 1 January 2020, as well as individuals hospitalized and deceased due to COVID-19 in 2020. The registries included the Statistics Norway (SSB) registry, the Norwegian Patient Registry (NPR), and Norway Control and Payment of Health Reimbursements (KUHR) registry, and the Norwegian Cause of Death Registry (DAR). These registries were linked using unique personal identification numbers. The NPR and SSB registries were used to extract age, immigration, and emigration dates for all inhabitants of Norway. The KUHR registry provided information on medical diagnoses in primary and secondary outpatient care using the International Classification of Primary Care (ICPC-2/ICPC-2B) and ICD-10 codes, respectively [10,11]. The NPR provided information on medical diagnoses in specialist outpatient and inpatient care, using ICD-10 coding. Both

KUHR and NPR provided medical diagnosis data since 1 January 2010. DAR provided information on mortality.

Definitions of severe COVID-19

COVID-19 Hospitalization was defined as hospital admission for at least 24 hours and i) a primary diagnosis with ICD-10 code U071, U072, or U109; or ii) a secondary diagnosis with ICD-10 code U071, U072, or U109 combined with a primary code of respiratory illness (defined as any of the ICD-10 J-codes). This definition was based on prior research in Norway [12].

Death due to COVID-19 was defined as individuals with either i) COVID-19 listed as the primary cause of death (ICD-10 codes U071, U072, or U109 or ii) with a COVID-19 hospitalization in the 7 days preceding date of death. In the Dutch data registry, only the second definition was used, because cause of death was not available in death registry.

Risk classifications for severe COVID-19

The Dutch risk classification was obtained from the 'Adviesnota Vaststelling volwassen medische risicogroepen COVID-19-vaccinatiecampagne' ['Recommendation on establishing adult medical risk groups for the COVID-19 vaccination campaign'] in February 2023 [4]. This classification contains a list of chronic medical condition categories defined as either high- or moderate-risk for severe COVID-19. Each medical condition was independently coded using ICD-10 by two authors (AvB and IW), with no discrepancies found.

The Norwegian risk classification was obtained from the Norwegian Health Institute in July

2023 [5]. This scheme includes chronic medical condition categories with corresponding

ICPC-2 and ICD-10 codes classified as either high-risk or increased-risk, which we renamed

as high- and moderate-risk for consistency with other classifications.

The European risk classification was obtained from the 'Core protocol for ECDC studies of

COVID-19 vaccine effectiveness against hospitalization with Severe Acute Respiratory

Infection (SARI), laboratory-confirmed with SARS-CoV-2 or with seasonal influenza –

Version 3.0' dated February 2024 [6]. This protocol provides ICD-10 codes for medical

condition categories that are mandatory or optional for reporting in the ECDC studies. We

classified the former medical condition categories as high-risk and the latter as moderate-risk.

Individuals in the Dutch or Norwegian datasets were assigned to have moderate- or high-risk

chronic medical conditions if at least one relevant ICD-10 (both datasets) or ICPC-2 code

(Norwegian cohort only) was recorded for that individual within the six months prior to 1

January 2020. For cancer diagnoses, records within five years prior to 1 January 2020 were

used. These timeframes were defined according to the criteria specified in the classifications.

Different medical risk classifications may use different codes for the same chronic medical

condition, as each classification was developed with its own coding system. The ICD-10 and

ICPC-2 codes used for this analysis are detailed in **Supplementary Tables 1-3**.

Individuals with one or more high-risk chronic medical condition categories, regardless of

whether they also had one or more moderate-risk conditions, were defined as being at high-

risk for severe COVID-19. Individuals with one or more moderate-risk chronic medical

condition categories and no high-risk chronic medical condition were defined as being at

moderate-risk for severe COVID-19. Individuals without any listed chronic medical

condition categories were defined as low-risk. Pregnancy was not considered a criterion for

categorizing individuals into the high- or moderate-risk groups in all classifications.

Statistical Analysis

Data for the Netherlands and Norway were analyzed separately. Descriptive analyses were

performed to compare the respective national with the ECDC classification. The prevalence

of high- and moderate-risk medical condition categories, and the most frequent combinations

of medical condition categories, were shown in upset plots which visualize co-occurance of

chronic medical condition categories in the population. Due to privacy reasons, numbers

below 10 for the Dutch data and below 5 for the Norwegian data were not shown.

We reported both absolute numbers and proportions of individuals by 10-year age groups,

classified into high-, moderate-, and low-risk groups for severe COVID-19. The discordance

between the European and each national classification was calculated as the proportion of the

population with a different European versus national risk status and visualized with matrix

plots. Moreover, to understand the difference between the Dutch and Norwegian

classifications, discordance was also calculated for the hospitalized and deceased populations

in Norway. Different medical risk classifications may use different codes for the same

chronic medical condition because they were formulated as such by the classifications. The

95% confidence intervals (CI) of discordance and concordance proportions were calculated

using the Clopper-Pearson method [13].

To understand the factors related to discordance, we visualized the co-occurance of chronic

medical condition categories in the discordant general, hospitalized, and deceased

183 populations with upset plots. Also, to understand how coding differences affect overall

184 discordance, we reviewed the most prevalent diseases in hospitalized and deceased

185 populations one by one by assessing the differences in population sizes between

186 classifications. Since the Netherlands and Norway consider individuals above a certain age as

187 high-risk for severe COVID-19, we also assessed the discordance in the general population in

188 three scenarios: 1) the entire population regardless of age, 2) individuals younger than 60

189 years of age, aligning with the Dutch schemes [14], and 3) individuals younger than 65 years

190 of age, aligning with the Norwegian schemes [5].

192 A sensitivity analysis was conducted to assess the importance of the reference date by

193 evaluating the discordance in the general population for 1 January 2018, 1 January 2019, and

194 1 January 2021, instead of 1 January 2020.

Code Availability

197 The codes reproducing the results of this study are publicly available at

198 https://github.com/IWesterhof/COVID-19-risk-classifications.

Data Availability

201 The aggregated tables of counts generated and analyzed in this study are publicly available at

202 https://github.com/IWesterhof/COVID-19-risk-classifications.

203 Results are based on calculations by the authors using non-public microdata from Statistics

204 Netherlands. Under certain conditions, these microdata are accessible for statistical and

205 scientific research. For further information: microdata@cbs.nl.

Ethics

The analyses conducted with data from the Netherlands did not fall under the scope of the

Dutch Medical Research Involving Human Subjects Act (WMO) and, therefore, did not

require approval from an accredited ethics committee in the Netherlands. For the analyses

conducted with data from Norway, the Regional Committee for Medical and Health Ethics of

South/East Norway (no. 285687) approved the study. The Norwegian Data Protection

Services for research and the University of Oslo approved the Data Protection Impact

Assessment – DPIA (no. 341884).

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data

interpretation, or writing of the report. The corresponding author had full access to all the

data in the study and had final responsibility for the decision to submit for publication.

Results

The Dutch cohort contained records of 17.4 million individuals (median age 42, interquartile

range (IQR) 22-60), while the Norwegian cohort contained records of 5.6 million individuals

(median age 39, IQR 21-57).

Comparison of risk classifications for severe COVID-19

Chronic medical condition categories included in the European, Dutch, and Norwegian risk classifications and their respective risk groups for severe COVID-19 are shown in **Table 1**. Several chronic medical condition categories were consistently considered high-risk (e.g., cancer, immunodeficiency, and organ transplants) and moderate-risk (e.g., dementia) in the European and national classifications. There was some variability in the risk classifications of other conditions. Obesity was considered high-risk in the European classification but moderate-risk in both national classifications; lung disease, cardiovascular disease, and diabetes mellitus were considered high-risk in the European classification but moderate-risk in both national classifications. Hypertension was only listed in the European classification. Down syndrome and neurological disorders with impaired breathing were not included in the European classification but were considered high-risk in both national classifications.

Classification of the general population by risk for severe COVID-19

Based on the national classifications, the most prevalent chronic medical condition categories in the Netherlands were lung disease, followed by cardiovascular disease, reduced immunity, and neurological/-muscular disorder; all classified as moderate-risk (**Figure 1 A**). In Norway, the most prevalent conditions were cardiovascular disease, lung disease, and diabetes mellitus; these were also classified as moderate-risk (**Figure 1 B**). Based on the European classification, the most prevalent chronic medical condition categories in the Netherlands were cardiovascular disease, hypertension, and cancer, and in Norway cardiovascular disease, diabetes mellitus, and cancer; all classified as high-risk (**Figure 1 C-D**). Differences in the prevalence between classifications arise from variations in the diagnosis codes to define a specific medical risk condition. For example, in the Netherlands, 0.54% of the population

250 **Table 1. Comparison of European and national risk classifications for severe COVID-19.** Chronic

251 medical condition categories based on ICD-10 and ICPC-2 codes (see **Supplementary Tables 1-3)** and

252 their respective risk groups for severe COVID-19 are shown. Different medical risk classifications may use

253 different codes for the same chronic medical condition.

Chronic medical condition categories	Classification		
	European	Dutch	Norwegian
Cancer (solid organ and haematological)	High	High	High
Immunodeficiency	High	High	High
Organ transplant	High	High	High
Overweight and obesity	High	High	Moderate
Lung disease	High	Moderate	Moderate
Cardiovascular disease	High	Moderate	Moderate
Diabetes mellitus	High	Moderate	Moderate
Hypertension	High	low	low
Kidney disease dialysis required	Moderate	High	High
Anaemia	Moderate	High	low
Kidney disease	Moderate	Moderate	High
Liver disease/cirrhosis	Moderate	Moderate	High
Neurological/muscular disorder (without impaired breathing)	Moderate	Moderate	High
Dementia	Moderate	Moderate	Moderate
Tuberculosis	Moderate	Moderate	low
Stroke	Moderate	low	Moderate
Asplenia	Moderate	low	low
Rheumatologic disease	Moderate	low	low
Sickle cell disease	low	High	low
Down syndrome	low	High	High
Neurological disorder with impaired breathing	low	High	High
Reduced immunity	low	Moderate	Moderate
HIV infection	low	Moderate	low
Cochlear implants	low	Moderate	low

Risk due to chronic medical conditions   = High   = Moderate   = low

was classified as having cancer using the national classification, compared to 2.0% using the

European classification because this classification included seven additional ICD-10 codes

(**Supplementary Tables 1-2**). In Norway, 2.3% of the population was classified as having

cancer using the national classification compared to 2.1% using the European classification

due to differences in included codes.

In both countries and across all classifications, most individuals under 80 years of age were

assigned low-risk for developing severe COVID-19 (**Figure 2**). Among children and

adolescents (under 20 years old), 92.8% were classified as low-risk, 6.9% as moderate-risk,

and 0.3% as high-risk, according to national schemes, while this was 98.5%, 0.4%, and 1.2%,

respectively, according to the European classification. In Norway, the national classification

identified 98.5% as low-risk, 0.4% as moderate-risk, and 1.2% as high-risk, while this was

96.4%, 0.5%, and 3.1%, respectively, according to the European classification. In both

countries and across all classifications, the percentage of individuals in moderate- and high-

risk groups increased with age, reaching 41.1% and 53.6% for those over 80 years in the

national classifications, and 41.8% and 37.7% in the European classifications in the

Netherlands and Norway, respectively.

In the Netherlands and Norway, risk classification differed for 12.0% and 13.8% of the

general population, respectively, between the national and the European classification

schemes (**Figure 3 A-B**). The European classification assigned more people as high-risk (9%

in the Netherlands, 9.2% in Norway) compared to national classifications (1.5% and 3.0%,

respectively). Conversely, the national classifications identified more people as moderate-risk

(11.3% and 12.7%, respectively) than the European classification (1.0% and 1.3%,

respectively). According to the national classifications, 87.2% of the population in the

Netherlands and 84.4% in Norway were classified as low-risk. These percentages were

slightly higher using the European classification (90.1% and 89.5%, respectively).

Discordance for population with severe COVID-19 in 2020

The Netherlands had 39,063 hospitalizations (median age 70 years [IQR 58-78]) and 7,031 deaths (median age 78 years [IQR 71-83]). In Norway, there were 2,228 hospitalizations (median age 64 years [IQR: 51-78]) and 514 deaths (median age 84 years [IQR: 75-90]). Cardiovascular disease, classified as high-risk in the European classification and moderate-risk in the national classifications, is the most prevalent chronic condition among hospitalized and deceased individuals (**Supplementary Figure 1-2**). Another important disease that is prevalent and differently classified is Diabetes Mellitus.

For all ages and both countries, and similar to the general population, the European classification assigns more individuals to high-risk, while national classifications define more individuals as moderate-risk (**Supplementary Figures 3-4)**. Discordance was even higher among hospitalized (the Netherlands 36.5% and Norway 38.2%), and deceased (the Netherlands 46.6% and Norway 45.1%) populations, compared to the general population (discordance in the Netherlands 12.0% and Norway 13.8%), as shown in **Figure 3C-F.** Moreover, a large part of the hospitalized (51.5% in the Netherlands and 49.5% in Norway) and deceased (40.2% and 36.2%, respectively) populations was defined as low-risk in both classifications, which means these individuals had none of the chronic medical conditions listed in classifications.

Comparison between the Norwegian and Dutch classifications for the hospitalized and deceased populations in Norway shows a discordance of 17.1% and 21.8%, respectively (**Supplementary Figure 5**). This is mainly caused by differences in selecting diseases (ICD-19 and ICPC-2 codes) within the disease categories lung disease, cardiovascular disease, and dementia.

Discordance between risk classifications and the related factors

313
Discordance was higher in elderly because the number of individuals with one or more

medical risk conditions was higher than in younger age groups (**Figure 3-4; Supplementary**

Figure 6). **Figure 4** shows the chronic medical condition categories in the general population

who were classified differently by the European and respective national classification

schemes (the discordant population). In the discordant population in the Netherlands, 23.5%

had neurological/-muscular disorders, 23.8% reduced immunity, and 13.6% kidney disease

according to the national classification (**Figure 4A**). In the discordant population in Norway,

6.7% had reduced immunity, and 2.3% neurological/muscular disorders, classified as

moderate- and high-risk, respectively (**Figure 4B**). On the contrary, the European

classification included chronic medical condition categories that were not included in the

national classifications. In the Netherlands, examples were hypertension and kidney disease

with prevalences of 25.5% and 6.3% in the discordant population. In Norway, 8.2% of the

discordant population had hypertension and 3.6% had kidney disease according to European

schemes, but not included in national schemes. Unlike Norway, none of the discordant

individuals in the Netherlands were classified as overweight/obese or diabetic based on the

European classification. Similar was observed for the hospitalized and deceased discordant

populations (**Supplementary Figures 7-8**).

Some of the discordance in the most prevalent chronic medical condition categories (lung

disease, cardiovascular disease, diabetes mellitus, cancer, and kidney disease) among

hospitalized and deceased populations may stem from differences in ICD-10 and ICPC-2

codes. In the Netherlands, the national classification identified more individuals with lung

disease and diabetes, while the Norwegian system captured more cases across all disease

categories except kidney disease, indicating that it includes more ICD-10 codes

(**Supplementary Table 4**). The European classification identified more individuals with

cardiovascular disease and cancer in the Netherlands and more individuals with kidney

disease in Norway. Notably, in the Netherlands, cancer was better captured with the

European classification, identifying more cases in the general (2.0% versus 0.5%),

hospitalized (9.1% versus 4.1%), and deceased (10.8% versus 4.1%) populations compared to

the Dutch classification. Similarly, in Norway, the European classification identified more

individuals with kidney disease in the general (0.8% versus 0.2%), hospitalized (10.1%

versus 2.4%), and deceased (13.3% versus 2.3%) populations compared to the national

classification.

In the Netherlands, the most common chronic medical condition categories varied by age

group (**Supplementary Figures 9-10**). In those younger than 60 or 65, lung disease was the

most prevalent condition, followed by neurological/-muscular disorder and cardiovascular

disease. In Norway, the national classification showed no differences between all ages and

individuals younger than 65 and 60 years of age in most pronounced chronic conditions. In

the Netherlands, based on the European classification there was no change in the order of

most prominent conditions contributing to discordance in the population aged below 60 years

compared to all ages. In contrast, for those aged below 65 years, the most prevalent

conditions were cardiovascular disease, diabetes mellitus, and lung disease, but not

hypertension and cancer.

Sensitivity analyses

No meaningful differences in discordance percentages were observed when using different

reference dates to define the study populations (data not shown).

Discussion

In this multi-country, nationwide registry-linkage study, we compared the respective national

with the European medical risk classification for severe COVID-19, and classified the

populations of the Netherlands and Norway according to this risk, across different age

groups. For clarity, we reiterate that individuals with at least one high-risk chronic condition

were classified as high-risk, those with only moderate-risk conditions as moderate-risk, and

those without listed conditions as low-risk (see Methods for details). Our findings revealed

substantial differences between the national and European risk classifications in the general

population (discordance in the Netherlands 12.0% and Norway 13.8%), hospitalized patients

(the Netherlands 36.5% and Norway 38.2%), and deceased (the Netherlands 46.6% and

Norway 45.1%), with the European classification scheme assigning a broader range of

chronic medical condition categories to the high-risk category than the two national

classifications. Consequently, a larger proportion of the population is classified as high-risk

when using the European classification compared to the national classifications. Conversely,

a larger proportion of the population is classified as moderate-risk when using the respective

national classifications compared to the European classification. The Dutch national

classification may be underinclusive for cancer and cardiovascular disease, and the

Norwegian national classification for kidney disease, while those disease categories are

probably more clinically relevant as they are prevalent among hospitalized and deceased

populations. Interestingly, a large part of the hospitalized (51.5% in the Netherlands and

49.5% in Norway) and deceased (40.2% and 36.2%) populations were defined as low-risk in

both national and European classifications. This may be due to chronic medical conditions

not captured by either classification. This suggests that the classifications differ even more

when applied to severe COVID-19 outcomes and fail to identify a considerable share of

affected individuals.

These discrepancies may have implications for COVID-19 vaccination programs, which

prioritize specific risk populations. Although primarily designed for research focusing on

COVID-19 vaccine effectiveness and enhancing SARI surveillance in Europe, the European

protocols have influenced public health policy in the past, as demonstrated, for example, with

influenza vaccination strategies [15]. However, we recognize that this classification is

primarily surveillance-oriented and not an officially mandated European clinical standard.

While not a universal policy tool, this classification provides a structured framework that can

support public health decision-making alongside other clinical and epidemiological

considerations. Therefore, the European classification for severe COVID-19 could remain

relevant for broader public health decisions and policy. Our comparative analysis suggests

that using the European classification, 9.0% of the population in the Netherlands and 9.2% of

the population in Norway are high-risk due to chronic medical condition categories and

should be vaccinated, while these percentages are only 1.5% and 3.0%, respectively, when

using the national classifications. Vaccination programs that prioritize both moderate- and

high-risk groups, the European classification would result in 10.0% of the Dutch population

and 10.5% of the Norwegian population having to be vaccinated, compared to 12.8% and

13.7%, respecitively, if using the respective national classifications. Moreover, chronic

medical condition categories are defined based on different ICD-10 and ICPC-2 codes in the

three classifications, resulting in differences in prevalence of individual medical risk

categories across classifications. Therefore, the choice between the European or national

classifications may have important consequences for vaccination prioritization and coverage,

potentially influencing the impact of vaccination campaigns in preventing severe COVID-19.

The dominant medical condition categories generating the discordance in risk status were

lung and cardiovascular disease in both Norway and the Netherlands, neurological disorders

in the Netherlands, and diabetes in Norway. Hypertension was one of the most pronounced

discordant chronic condition categories between classifications. According to the European

classification, but not to the national ones, hypertension was considered a high-risk disorder

for severe COVID-19, and its prevalence estimate was 3.5% in the Netherlands and 1.4% in

Norway. Several studies have indicated that hypertension was not an independent predictor of

severe COVID-19 [16,17]. Therefore, the high-risk population might be overestimated in the

European classification. Lung disease, cardiovascular disease, and diabetes mellitus were also

among the most pronounced medical condition categories leading to discordance, which were

diagnosed in 1.7-4.6% of the population according to the national and European

classifications. These conditions were classified as moderate-risk in the national

classifications but as high-risk in the European classification. Although multiple studies have

shown an increased risk of severe COVID-19 in individuals with these medical condition

categories [18–20], it is unknown whether they should be part of the high- or moderate-risk

group. Interestingly, the European classification does not include Down syndrome and

neurological/-muscular disorder as risk factors for severe COVID-19, while the national

classifications consider them as moderate- or high-risk chronic conditions. Several studies

have demonstrated an increased risk of COVID-19 hospitalization and death among

individuals with Down syndrome [21,22] and multiple sclerosis [23,24]. However, our

findings show that only a very small fraction of the discordant population has Down

syndrome (≤0.2% in both countries), while those with neurological/muscular disorders make

up a larger proportion—23.5% in the Netherlands and 2.3% in Norway. This supports the

need to assess the discordant conditions in relation to severe COVID-19 to ensure vaccination

prioritization and coverage of individuals at high-risk.

Our study has several limitations. There is a potential underestimation of the population with

high- and moderate-risk for severe COVID-19 in the Netherlands. The detection of chronic

medical condition categories in the Netherlands relied solely on ICD-10 codes from hospital

discharge data. Individuals without recent hospital admission may be missed, as hospital data

might not capture those whose conditions are managed in primary care. Consequently, there

is a potential underestimation of the number of individuals at moderate- and high-risk.

However, the impact on the discordance between the national and the European

classifications is likely minimal, as both classifications are based exclusively on ICD-10

codes, irrespective of data source. Conversely, the analyses conducted for the population in

Norway, based on diagnostic records from both outpatient and inpatient specialist care, as

well as from primary care, were less susceptible to this bias. Another limitation is the absence

of ICD-10 codes for asplenia in the Norwegian registries. However, since asplenia is a very

rare condition, with 0.44 surgical asplenia per 100,000 person-years in Norway, it is unlikely

to affect our overall conclusions [25]. Lastly, the available data did not allow us to assess

how well the classifications predict severe COVID-19 outcomes such as hospitalization and

death. Due to limited testing capacity in 2020, we could not clearly identify exposed

individuals and analyze how their risk is associated with severe COVID-19 outcomes.

Future research should aim to establish a consensus on which chronic medical condition

categories are universally recognized as conferring moderate- and high-risk for severe

COVID-19. We propose a matched multi-country cohort study to estimate the risk of

hospitalization and death due to COVID-19 in individuals with and without specific chronic

conditions, accounting for confounders like age, vaccination status, and circulating variants.

Additionally, the importance of chronic medical conditions in the hospitalized and deceased

populations that are not included in the national and European classifications, and therefore

classified as low-risk, should be further assessed. This will help understand which additional

conditions should be included in a risk classification for severe COVID-19. The analyses

should ideally be conducted at the diagnostic code level, as our findings highlight substantial

differences between classifications for specific disease categories. This approach will also

help determine whether certain ICD-10 and ICPC-2 codes are overly broad or clinically

unsubstantiated. This research will be crucial for deciding which classification most

accurately captures the population at highest risk. Moreover, mathematical modeling studies

can help to understand the impact of different risk classifications and optimal vaccination

strategies [26–29]. Incorporating risk stratification into modeling studies has the potential to

design more effective strategies, a consideration often overlooked in current research efforts.

Furthermore, exploring emerging data sources and digital health technologies could improve

the identification and monitoring of moderate- and high-risk populations.

Conclusion

There are substantial differences between the European and the respective national medical

risk classifications for severe COVID-19 based on pre-existing chronic medical condition

categories, which may have important implications for vaccination strategies. The European

classification suggests that a larger proportion of the population is at high-risk for severe

COVID-19 and may require vaccination. The difference in classification is most pronounced

for chronic medical condition categories belonging to the categories of cardiovascular

disease, lung disease, and diabetes mellitus. Further research should identify to what extent

the discordant chronic conditions are associated with severe COVID-19 risk.

Author Contributions

Conceptualization: I Westerhof, G Rozhnova. Data management: I Westerhof, A de Boer.

Methodology: I Westerhof, A de Boer, G Rozhnova. Investigation: I Westerhof, A de Boer.

Formal analysis: I Westerhof, A de Boer. Visualization: I Westerhof. Writing—original draft:

I Westerhof, A de Boer, G Rozhnova. Writing—review and editing: I Westerhof, A de Boer,

A Lupattelli, I Slurink, O Boldea, HME Nordeng, JR Bosdriesz, F Pijpers, M Schim van der

Loeff, M Knol, JHHM van de Wijgert, P Bruijning, and G Rozhnova.

Declaration of interests

We declare no competing interests.

Acknowledgments

We are grateful to all the participating families in the Netherlands and Norway who are part

of the health registries and made this research possible. GR, IW, AdB, and OB were

supported by the ZonMw project (10430362220002). GR was supported by Fundação para a

Ciência e a Tecnologia project 2022.01448.PTDC, DOI 10.54499/2022.01448.PTDC. GR,

IW, AL, and PB were supported by the VERDI project (101045989), funded by the European

Union. Views and opinions expressed are however those of the author(s) only and do not

necessarily reflect those of the European Union or the Health and Digital Executive Agency.

Neither the European Union nor the granting authority can be held responsible for them. IW

was supported by the scholarship program iAPOGEE "International Alliance for

PharmacoGenetic Epidemiology Excellence" at the University of Oslo, Norway. Data

acquisition of the Norwegian data in this study was funded by HN's EU-COVID-19 project,

funded by the Norwegian Research Council's COVID-19 Emergency Call (project no.

509 31270). The work on the Norwegian data was performed on the TSD (Tjeneste for Sensitive

510 Data) facilities, owned by the University of Oslo, operated and developed by the TSD service

511 group at the University of Oslo, IT-Department (USIT) (tsd-drift@usit.uio.no).

513 Declaration of generative AI in scientific writing
514 During the preparation of this work the author(s) used Chat GPT in order to improve

515 readability and language. After using this tool/service, the author(s) reviewed and edited the

516 content as needed and take(s) full responsibility for the content of the publication.

References

[1] World Health Organization. Global Covid-19 Vaccination Strategy in a Changing World July 2022 update. 2022.

[2] Antos A, Kwong ML, Balmorez T, Villanueva A, Murakami S. Unusually High Risks of COVID-19 Mortality with Age-Related Comorbidities: An Adjusted Meta-Analysis Method to Improve the Risk Assessment of Mortality Using the Comorbid Mortality Data. Infect Dis Rep 2021;13:700–11. https://doi.org/10.3390/idr13030065.

[3] Zhang J, Dong X, Liu G, Gao Y. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clin Rev Allergy Immunol 2022;64:90–107. https://doi.org/10.1007/s12016-022-08921-5.

[4] Gezondheidsraad. Adviesnota Vaststelling volwassen medische risicogroepen COVID-19-vaccinatiecampagne. 2023.

[5] Norwegian Institute of Public Health. Coronavirus vaccine. Ups-and-Childrenadolescents-with-Underlying-Conditions 2023. https://www.fhi.no/en/id/corona/coronavirus-immunisation-programme/coronavirus-vaccine (accessed April 17, 2024).

[6] European Centre for Disease Prevention and Control. Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza - Version 3.0. 2024.

[7] European Centre for Disease Prevention and Control. Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0. Stockholm: 2021.

[8] Norwegian Institute of Public Health. Coronavirus vaccine 2020. https://www.fhi.no/en/id/corona/coronavirus-immunisation-programme/coronavirus-vaccine (accessed September 1, 2022).

[9] Gezondheidsraad. Advies Strategieën voor COVID-19-vaccinatie. 2020.

[10] World Health Organization. International Statistical Classification of Diseases Related Health Problems 10th Revision Geneva. Https://IcdWhoInt/Browse10/2019/En 2019.

[11] World Health Organization. International Classification of primary care, 2nd edition (ICPC-2). Https://WwwWhoInt/Standards/Classifications/Other-Classifications/International-Classification-of-Primary-Care 2024.

[12] Whittaker R, Toikkanen S, Dean K, Lyngstad TM, Buanes EA, Kløvstad H, et al. A comparison of two registry-based systems for the surveillance of persons hospitalised with COVID-19 in Norway, February 2020 to May 2022. Eurosurveillance 2023;28. https://doi.org/10.2807/1560-7917.ES.2023.28.33.2200888.

[13] Clopper CJ, Pearson ES. The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial. Biometrika 1934;26:404. https://doi.org/10.2307/2331986.

[14] Rijksinstituut voor Volksgezondheid en Milieu. COVID-19 vaccination 2024. https://www.rivm.nl/en/coronavirus-covid-19/vaccination (accessed April 22, 2024).

[15] Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber JT, et al. Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Eurosurveillance 2014;19. https://doi.org/10.2807/1560-7917.ES2014.19.16.20780.

[16] D'Elia L, Giaquinto A, Zarrella AF, Rendina D, Iaccarino Idelson P, Strazzullo P, et al. Hypertension and mortality in SARS-COV-2 infection: A meta-analysis of

observational studies after 2 years of pandemic. Eur J Intern Med 2023;108:28–36.
https://doi.org/10.1016/j.ejim.2022.11.018.

[17] Fresán U, Guevara M, Trobajo-Sanmartín C, Burgui C, Ezpeleta C, Castilla J.
Hypertension and Related Comorbidities as Potential Risk Factors for COVID-19
Hospitalization and Severity: A Prospective Population-Based Cohort Study. J Clin
Med 2021;10:1194. https://doi.org/10.3390/jcm10061194.

[18] Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with
mortality and disease severity among 167,500 individuals with COVID-19 in Canada:
A population-based cohort study. PLoS One 2021;16:e0258154.
https://doi.org/10.1371/journal.pone.0258154.

[19] Wee LE, Tan JYJ, Chiew CJ, Abisheganaden JA, Chotirmall SH, Lye DCB, et al. A
Nationwide Cohort Study of Delta and Omicron SARS-CoV-2 Outcomes in
Vaccinated Individuals With Chronic Lung Disease. Chest 2024.
https://doi.org/10.1016/j.chest.2024.05.017.

[20] Rainer L, Bachner F, Eglau K, Ostermann H, Siebert U, Zuba M. Comorbidities and
COVID-19 hospitalization, ICU admission and hospital mortality in Austria. Wien
Klin Wochenschr 2022;134:856–67. https://doi.org/10.1007/s00508-022-02036-9.

[21] Bedston S, Almaghrabi F, Patterson L, Agrawal U, Woolford L, Anand SN, et al. Risk
of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a
pooled analysis of national prospective cohort studies involving 7.4 million adults in
England, Northern Ireland, Scotland and Wales. The Lancet Regional Health - Europe
2024;37:100816. https://doi.org/10.1016/j.lanepe.2023.100816.

[22] Semenzato L, Botton J, Drouin J, Cuenot F, Dray-Spira R, Weill A, et al. Chronic
diseases, health conditions and risk of COVID-19-related hospitalization and in-
hospital mortality during the first wave of the epidemic in France: a cohort study of 66
million people. The Lancet Regional Health - Europe 2021;8:100158.
https://doi.org/10.1016/j.lanepe.2021.100158.

[23] Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C. Increased
risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational
studies. J Neurol 2022;269:1114–20. https://doi.org/10.1007/s00415-021-10803-3.

[24] Moreno-Torres I, Meca Lallana V, Costa-Frossard L, Oreja-Guevara C, Aguirre C,
Alba Suárez EM, et al. Risk and outcomes of COVID-19 in patients with multiple
sclerosis. Eur J Neurol 2021;28:3712–21. https://doi.org/10.1111/ene.14990.

[25] Orangzeb S, Watle SV, Caugant DA. Adherence to vaccination guidelines of patients
with complete splenectomy in Norway, 2008–2020. Vaccine 2023;41:4579–85.
https://doi.org/10.1016/j.vaccine.2023.06.034.

[26] Béraud G. Mathematical models and vaccination strategies. Vaccine 2018;36:5366–72.
https://doi.org/10.1016/j.vaccine.2017.10.014.

[27] Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-
informed COVID-19 vaccine prioritization strategies by age and serostatus. Science
(1979) 2021;371:916–21. https://doi.org/10.1126/science.abe6959.

[28] Viana J, van Dorp CH, Nunes A, Gomes MC, van Boven M, Kretzschmar ME, et al.
Controlling the pandemic during the SARS-CoV-2 vaccination rollout. Nat Commun
2021;12:3674. https://doi.org/10.1038/s41467-021-23938-8.

[29] Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to
vaccinate first? Sci Adv 2021;7. https://doi.org/10.1126/sciadv.abf1374.

Figure 1. Chronic conditions in the general population. A-B) National and **C-D)** European medical risk classification for severe COVID-19. In all classifications, chronic medical

condition categories were assigned if registered in the past six months prior to 1 January 2020, except for cancer which was assigned if registered in the prior five years. The left bars

show the number and proportion of each chronic medical condition category in the population. Orange bars indicate the high-risk chronic conditions according to the classification,

while blue bars indicate moderate-risk chronic conditions. The dots represent the presence of one or more chronic medical condition categories in an individual, with the upper bars

showing the combinations that occur in at least 1% of the general population.

Figure 2. Classification of the general population by risk for severe COVID-19. Population shown as absolute numbers (top) and proportions (bottom) classified by age and risk for severe COVID-19 due to chronic medical condition categories in the **A-B)** national and **C-D)** European classifications.

Figure 3. Discordance in assigning risk status to individuals between the European and national classifications in the A-B) general population, **C-D)** hospitalized population, and **E-F)** deceased population. The discordance between the European and each national classification was calculated as the proportion of the general populations with a different risk status (off-diagonal elements). Concordance is the proportion of the population classified into the same risk group (diagonal elements). Since every individual belongs to one of the risk groups, the elements of the matrix plots add up to 100%.

Figure 4. Chronic conditions in the discordant general population. A-B) National and **C-D)** European medical risk classification for severe COVID-19. In all classifications, chronic medical condition categories were those that had been registered in the past six months prior to 1 January 2020, except for cancer which was included as a chronic medical condition if registered in the past five years preceding 1 January, 2020. The dots represent the presence of one or more chronic medical condition categories. The left bars show the number and proportion of each chronic medical condition category in the population. Orange bars indicate the high-risk chronic conditions according to the classification, while blue bars indicate moderate-risk chronic conditions. The upper bars show the combinations of chronic conditions that occur in at least 1% of the discordant general population.